COFEPRIS Grants Emergency Use Authorization for Patria Vaccine
In a significant development, the Federal Commission for the Protection against Health Risks (COFEPRIS) has granted emergency use authorization to the Patria vaccine against COVID-19, developed by Laboratorio Avimex S.A. de C.V. This decision follows meticulous technical scrutiny and a favorable assessment of the vaccine's clinical efficacy.
COFEPRIS's rigorous standards have earned international recognition, with authorizations acknowledged by over 20 countries across Latin America and the Caribbean. This facilitates broader access to the vaccine, underscoring COFEPRIS's standing as a level 4 regulatory agency comparable to esteemed counterparts such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
It is crucial for the public to adhere to medical guidelines and national vaccination protocols to ensure the safe and effective administration of the Patria vaccine. Any adverse events should be promptly reported to pharmacovigilancia@cofepris.gob.mx - mailto:pharmacovigilancia@cofepris.gob.mx. This directive reinforces COFEPRIS's commitment to transparency and the safeguarding of public health.
The approval of the Patria vaccine marks a significant milestone in Mexico's efforts to combat COVID-19, offering hope for enhanced protection and resilience against the virus nationwide.
Regulatory Impact
- Top Priority: No
- Type of Certificate: Yes
- Spectrum Bands: No
- Import Changes HS Codes: No
- Standard Changes: No
- Products Changes: Yes
- Label Changes: No
Regulatory Impact
| Impact Type | Status |
|---|---|
| Top Priority | |
| Type Certificate | |
| Spectrum Bands | |
| Import Changes (HS Codes) | |
| Standard Changes | |
| Product Changes | |
| Label Changes |